Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ALPS

ALPS Group Inc

0.3885

Aug 04 • 9:58 AM ET -0.0084 (-2.12%)

Healthcare Biotechnology Malaysia Micro NASD

Peers: ACOG AGEN CNTB GALT IMUX IPHA KZIA SPRO VRCA VTVT

Scroll to Statements

Index	-
Market Cap	64.64M
Enterprise Value	70.19M
Income	-2.73M
Sales	0.00M
Book/sh	-3.19
Cash/sh	0.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	Feb 13, 2023
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Dec 23, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	179.56
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.04
Current Ratio	0.04
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-0.73
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	-175.18% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-610.86%
Sales Y/Y TTM	-
EPS Q/Q	-1113.92%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	72.96%
Insider Trans	0.00%
Inst Own	0.30%
Inst Trans	-12.66%
ROA	-17.24%
ROE	-62.50%
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-18.12%
SMA50	-35.12%
SMA200	-73.58%
Trades

Shs Outstand	166.40M
Shs Float	44.99M
Short Float	0.07%
Short Ratio	0.28
Short Interest	0.03M
52W High	15.00 -97.41%
52W Low	0.40 -1.65%
Volatility	3.96% 7.48%
ATR (14)	0.04
RSI (14)	23.50
Beta	-
Rel Volume	1.60
Avg Volume	110.18K
Volume	22,557

Perf Week	-16.52%
Perf Month	-33.40%
Perf Quarter	-57.73%
Perf Half Y	-60.54%
Perf YTD	-55.31%
Perf Year	-96.69%
Perf 3Y	-96.37%
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	0.40
Price	0.39
Change	-2.12%

Jun-23-26 08:05AM	Alps Group Inc Launches Patient-Derived Organoid Program to Advance Personalized Cancer Care in Southeast Asia (GlobeNewswire)
Jun-09-26 08:05AM	Alps Group Inc Expands MyGenome Accreditation to Include Whole Genome Sequencing Under MS ISO 15189:2022 (GlobeNewswire)
May-19-26 04:05PM	Alps Group Inc Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire) -8.99% -11.36%
Apr-17-26 08:30AM	Alps Group Appoints Former Ernst & Young Partner to Board of Directors, Strengthening Governance and Capital Markets Oversight (GlobeNewswire)
Feb-23-26 08:00AM	Alps Group Inc Publishes Clinical Safety, Tolerability and Effectiveness Data Supporting Advancement of Its Autologous NK Cell Pipeline Using an In-House Developed Culture Protocol (GlobeNewswire)
08:00AM	Loading…
Jan-30-26 08:00AM	Alps Group Inc Announces Potential Pipeline Expansion Beyond CELESOME(+) Following Publication of Nebulized Human Umbilical Cord Mesenchymal Stem Cell Exosome Therapy (GlobeNewswire)
Jan-08-26 08:00AM	Alps Group Inc Appoints Cheing Lye-Ping as Chief Financial Officer (GlobeNewswire)
Oct-31-25 08:00AM	Alps Announces Closing of Business Combination with Globalink Investment Inc. (GlobeNewswire) -14.67%

Alps Group, Inc. operates as a biotechnology company that integrates research and development, medical services, and wellness solutions. The company focuses on creating a fair healthcare ecosystem, to make advance predictive, preventive, and precision medicine accessible and affordable. The company is headquartered in Kuala Lumpur, Malaysia.

PhDSeng Kong Tham

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALPS

ALPS Group Inc

Upgrade your Finviz experience